Dallas, Texas 04/17/2014 (FINANCIALSTRENDS) – Gilead Sciences, Inc. (NASDAQ:GILD) disclosed last week positive and encouraging data from two of its ongoing phase 2 clinical trials for its target drug Sovaldi which is made of chemical compound sofosbuvir.
The results included data collected by administering 400 mg of the target drug into patients who are suffering from hepatitis C virus caused liver ailments. The data was also presented for peer review by the firm at the recently concluded 49th The International Liver Congress 2014. This event was held in London.
Explaining the importance of the data findings, Gilead Sciences, Inc. (NASDAQ:GILD) Chief Scientific Officer who also holds the designation of Executive Vice President of Research and Development Norbert Bischo$fberger, PhD has been quoted to have said that, “The patients included in these analyses are historically among the most difficult to cure, and many have had no appropriate treatment options until now. These data demonstrate that Sovaldi-based oral therapy can improve outcomes, has a favourable safety profile and is well tolerated among hepatitis C patients with severe liver disease.”
The first phase 2 tests involved a 48 week testing process, in which the first 24 weeks were limited to observing the 22 patients suffering from liver disease cirrhosis, who had been enrolled into the program. The data collected indicated that of the 22 patients who completed the 24 week treatment phase, 21 patients were observed to have benefited from the suppression of the virus in the liver. The data also indicated that the safety aspects of treatment form the target drug was well taken care of as only one patient discontinued the treatment due to unintended effects.
The second set of data released was related to Phase 2 testing involved patients who had been through a liver transplantation. They went through 24 weeks of testing process in which 70 percent of the patients showed progress in their prognosis.